Pulmonary manifestations of polymyositis/dermatomyositis

Clinical Pulmonary Medicine

Volumn 13, Issue 1, 2006, Pages 37-52

  Allan, Patrick F ^a   Kehoe, Kimberly ^a   Abouchahine, Sahar ^a   Brewer, Jonathan ^a   Emmons, Ethan E ^a   Morris, Michael J ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Antisynthetase; Aspiration; Dermatomyositis; Lung; Polymyositis; Pulmonary disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE;

ARTICLE; AUTOIMMUNE DISEASE; BRONCHIOLITIS OBLITERANS; DERMATOMYOSITIS; DISEASE COURSE; DYING; EPIDEMIOLOGICAL DATA; HISTOLOGY; HUMAN; HYGIENE; IMMUNE RESPONSE; INTERSTITIAL LUNG DISEASE; LARYNX; LUNG ALVEOLUS; LUNG BLOOD VESSEL; LUNG COMPLICATION; LUNG PARENCHYMA; LUNG TUMOR; MEDIASTINUM DISEASE; MORBIDITY; MUSCULOSKELETAL DISEASE; MYOPATHY; PATHOPHYSIOLOGY; PLEURA DISEASE; PNEUMONIA; POLYMYOSITIS; PROGNOSIS; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE; SLEEP DISORDER; VASCULAR DISEASE; WEAKNESS;

EID: 31044439770     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000197384.95536.25     Document Type: Article

References (206)

1. Targoff I. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993;100:116S-123S.
2. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighboring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68:472-478.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.
4. Arsura E, Greenberg A. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum. 1988;18:29-37.
5. Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis, a computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985;28:249-255.
6. Frazier A, Miller R. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65:403-407.
7. Lakhanpal S, Lie J, Conn D. Pulmonary disease in polymyositis/ dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis. 1987;46:23-29.
8. Medsger T, Robinson H, Masi A. Factors affecting survivorship in polymyositis, a life-table study of 124 patients. Arthritis Rheum. 1971;14:249-258.
9. Tazelaar H, Viggiano R, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141:727-733.
10. Takizawa H, Shiga J, Moroi Y, et al. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol. 1987;14:102-107.
11. Marie I, Hatron P, Hachulla E, et al. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25:1336-1343.
12. Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine. 2004;83:35-42.
13. Xue L, Chen X, Chen S. Prognostic factors of dermatomyositis: analysis of 119 cases. Chinese J Intern Med. 1997;36:32-35.
14. Porkodi R, Shanmuganandan K, Parthiban M, et al. Clinical spectrum of inflammatory myositis in south India - a ten year study. J Assoc Physician India. 2002;50:1255-1258.
15. Maugars YM, Berthelot JM, Abbas A, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263-274.
16. Marie I, Hatron P, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine. 1999;78:139-147.
17. Marie I, Hachulla E, Hatron P-Y, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2236.
18. Holden D, Brownell A, Fritzler M. Clinical and serologic features of patients with polymyositis and dermatomyositis. Can Med Assoc J. 1985;132:649-653.
19. Rose A, Walton J. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966;89:747-768.
20. Marie I, Hachulla E, Levesque H, et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol. 1999;26:2706-2709.
21. Lorenz R, Jorysz G, Tornieporth N, et al. The gastroenterologist's approach to dysphagia. Dysphagia. 1993;8:79-82.
22. De Merieux P, Verity M, Clements P, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis: clinical, radiographic and pathologic features. Arthritis Rheum. 1983;26:961-968.
23. De Rooij D, Van De Putte L, Habets W, et al. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin Rheumatol. 1989;8:231-237.
24. Rowen A, Reichel J. Dermatomyositis with lung involvement, successfully treated with azathioprine. Respiration. 1983;44:143-146.
25. Hepper N, Ferguson R, Howard F. Three types of pulmonary involvement in polymyositis. Med Clin North Am. 1964;48:1031-1042.
26. Koh ET, Scow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52:857-861.
27. Carpenter J, Bunch T, Engel A, et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol. 1977;4:207-214.
28. Grünebaum M, Salinger H. Radiologic findings in polymyositis- dermatomyositis involving the pharynx and upper oesophagus. Clin Radiol. 1971;22:97-100.
29. Hochberg M, Feldman D, Stevens M. Adult onset polymyositis/ dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986;15:168-178.
30. Kagen L, Hochman R, Strong E. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630-636.
31. Porubsky ES, Murray JP, Pratt LL. Cricopharyngeal achalasia in dermatomyositis. Arch Otolaryngol. 1973;98:428-429.
32. Kleckner FS. Dermatomyositis and its manifestations in the gastrointestinal tract. Am J Gastroenterol. 1970;53:141-146.
33. Horowitz M, McNeil J, Maddern G, et al. Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology. 1986;90:434-439.
34. Oddis CV. Therapy for myositis. Curr Opin Rheumatol. 1993;5:742-748.
35. Oddis CV. Therapy of inflammatory myopathy. Rheum Dis Clin North Am. 1994;20:899-918.
36. Dalakas MC. Current treatment of inflammatory myopathies. Curr Opin Rheumatol. 1994;5:595-601.
37. Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol. 1996;8:544-551.
38. Chodosh P. Cricopharyngeal myotomy in the treatment of dysphagia. Laryngoscope. 1975;85:1862-1873.
39. Dietz F, Logeman J, Sahgal V, et al. Cricopharyngeal muscle dysfunction in the differential diagnosis of dysphagia in polymyositis. Arthritis Rheum. 1980;23:491-495.
40. St. Guily J, Perie S, Willig T, et al. Swallowing disorders in muscular diseases: functional assessment and indications of cricopharyngeal myotomy. Ear Nose Throat J. 1994;73:34-40.
41. Black L, Hyatt R. Maximal static respiratory pressures in generalized neuromuscular disease. Am Rev Respir Dis. 1971;103:641-650.
42. Disdier P, Harle JR, Chrestian MA, et al. Extensive pharyngeal necrosis: an unusual complication of dermatomyositis. Rev Med Interne. 1992;13:218-220.
43. Hoffman GS, Franck WA, Raddatz DA, et al. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital. Am J Med. 1983;75:433-438.
44. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98:637-666.
45. Dickey B, Myers A. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum. 1984;14:60-76.
46. Schiavi E, Roncoroni A, Puy R. Isolated bilateral diaphragmatic paresis with interstitial lung disease: an unusual presentation of dermatomyositis. Am Rev Respir Dis. 1984;129:337-339.
47. Mahler D. Dyspnea and muscle weakness in a 65-year-old woman. Chest. 1992;102:1875-1876.
48. Hyun B, Diggs C, Toone E. Dermatomyositis with cystic fibrosis (honeycombing) of the lung. Dis Chest. 1962;42:449-453.
49. Blumbergs P, Byrne E, Kakulas B. Polymyositis presenting with respiratory failure. J Neurol Sci. 1984;65:221-229.
50. Selva-O'Callaghan A, Sanchez-Sitjes L, Munoz-Gall X, et al. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology. 2000;39:914-916.
51. Roach D, Salter W. Inflammatory disease-polymyositis with pulmonary infiltrate and pleural effusion. Minn Med. 1980:277-281.
52. Braun N, Arora N, Rochester D. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax. 1983;38:616-623.
53. Martin L, Chalmers I, Dhingra S, et al. Measurements of maximum respiratory pressures in polymyositis and dermatomyositis. J Rheumatol. 1985;12:104-107.
54. Sano M, Suzuki M, Sato M, et al. Fatal respiratory failure due to polymyositis. Intern Med. 1994;33:185-187.
55. Takase Y, Inoue K, Mannen T. Acute respiratory failure in polymyositis. J Neurol. 1989;236:123-125.
56. Haskard D. Successful treatment of dermatomyositis complicated by ventilatory failure. Ann Rheum Dis. 1983;42:460-461.
57. Astudillo L, Carreiro M, Sailler L, et al. Hypercapnic coma due to diaphragmatic involvement in a patient with dermatomyositis. Clin Exp Rheumatol. 2001;19:456-458.
58. Pearson CM, Currie S. Polymyositis and related disorders. In: Walton JN, ed. Disorders of Voluntary Muscle. Edinburgh: Churchill; 1974:614-652.
59. Janssens S, Decramer M. Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases. Chest. 1989;95:1160-1162.
60. De Reuck J, DeCoster W, Inderadjaja N. Acute viral polymyositis with predominant diaphragm involvement. J Neurol Sci. 1977;33:453-460.
61. Leano A, Miller K, White A. Chronic graft-versus-host disease-related polymyositis as a cause of respiratory failure following allogeneic bone marrow transplant. Bone Marrow Transplant. 2000;26:1117-1120.
62. Rini B, Gajewski T. Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide. Ann Oncol. 1999;10:973-979.
63. Yamaguchi Y, Sakurai Y, Mannen T, et al. Rapidly progressive polymyositis with elevated antiacetylcholine receptor antibody activity. Intern Med. 2000;39:1108-1110.
64. Ago T, Nakamura M, Iwata I, et al. Dermatomyositis associated with invasive thymoma. Intern Med. 1999;38:155-159.
65. Piper A. Sleep abnormalities associated with neuromuscular disease: pathophysiology and evaluation. Semin Respir Crit Care Med. 2002;23:211-219.
66. White DP, Douglas NJ, Pickett CK, et al. Sleep deprivation and the control of ventilation. Am Rev Respir Dis. 1983;128:984-986.
67. Phillips BA, Cooper KR, Burke TV. The effect of sleep loss on breathing in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987;91:29-32.
68. Grau J, Miro O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol. 1996;23:1921-1926.
69. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614-622.
70. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501-508.
71. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273-284.
72. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360-374.
73. Targoff I. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheum Reports. 2002;4:434-441.
74. Miró. Survival of patients with polymyositis/dermatomyositis and pulmonary involvement. J Rheumatol. 1999;26:1852-1853.
75. Bjoraker J, Ryu J, Edwin M, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.
76. Horiki T, Ichikawa Y, Moriuchi J, et al. HLA class II haplotypes associated with pulmonary interstitial lesions of polymyositis/dermatomyositis in Japanese patients. Tissue Antigens. 2002;59:25-30.
77. Arnett F, Hirsch T, Bias W, et al. The Jo-1 Antibody system in myositis: relationships to clinical features and HLA. J Rheumatol. 1981;8:925-930.
78. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12:475-481.
79. Friedman A, Targoff I, Arnett F. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459-467.
80. Walker EJ, Tymms KE, Webb J, et al. Improved detection of anti-Jo-1 antibody, a marker for myositis, using purified histidyl-tRNA synthetase. J Immunol Meth. 1987;96:149-156.
81. Oddis CV, Mesger TA, Cooperstein LA. A subluxing athropathy associated with the ati-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 1990;33:1640-1645.
82. Yoshida S, Akizuki M, Mimori T, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. Arthritis Rheum. 1983;26:604-611.
83. Hochberg MC, Feldman D, Stevens MB, et al. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984;11:663-665.
84. Hirakata M, Mimori T, Akizuki M, et al. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992;35:449-456.
85. Leu C, Joung-Liang L. Anti-Jo-1 antibody in patients with polymyositis/dermatomyositis. Chinese J Microbiol Immunol. 1992;25:41-47.
86. Targoff IN, Trieu EP, Miller FW. Reaction of Anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556-2564.
87. Targoff I, Arnett F. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990;88:241-251.
88. Robinson C, Callow M, Stevenson S, et al. Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis. Respir Res. 2001;2:119-124.
89. Gelpi C, Martinez MA, Vidal S, et al. Autoantibodies to a transfer RNA-associated protein in a murine model of chronic graft versus host disease. J Immunol. 1994;152:1989-1999.
90. Magro C, Morrison C, Pope-Harman A, et al. Direct and indirect immunofluorescence as a diagnostic adjunct in the interpretation of nonneoplastic medical lung disease. Am J Clin Pathol. 2003;119:279-289.
91. Whitaker J, Engel W. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972;286:333-338.
92. Ito M, Kaise S, Suzuki S, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462-467.
93. Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med. 2002;41:584-588.
94. Douglas W, Tazelaar H, Hartman T, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182-1185.
95. Kadono T, Kikuchi K, Kubo M, et al. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol. 1996;35:392-397.
96. Songcharoen S, Raju S, Pennebaker J. Interstitial lung disease in polymyositis and dermatomyositis. J Rheumatol. 1980;7:353-360.
97. Yang Y, Fujita J, Tokuda M, et al. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with polymyositis/dermatomyositis. Intern Med. 2002;41:1135-1141.
98. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245-250.
99. Sontheimer R. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387-408.
100. Takizawa H, Ito K. Cyclophosphamide pulse therapy for rapidly progressive interstitial pneumonia in dermatomyositis. A new possibility for rescue? Intern Med. 1997;36:448-449.
101. Manganelli P, Salaffi F, Pesci A. Clinical and subclinical alveolitis in connective tissue diseases assessed by bronchoalveolar lavage. Semin Arthritis Rheum. 1997;26:740-754.
102. Wallaert B, Hatron P, Grosbois J, et al. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage, relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis. 1986;133:574-580.
103. Takada T, Suzuki E, Nakano M, et al. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med. 1998;37:669-673.
104. Komocsi A, Kumanovics G, Zibotics H, et al. Alveolitis may persist during treatment that sufficiently controls muscle inflammation in myositis. Rheumatol Int. 2001;20:113-118.
105. Lee Y, Choi S, Ji J, et al. Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. Korean J Intern Med. 2000;15:85-88.
106. Kinebuchi S, Mizuno K, Moriyama H, et al. Two cases of interstitial pneumonia with anti-Jo-1 antibodies in the absence of myositis. Nihon Kokyuki Gakkai Zasshi. 2003;41:739-745.
107. Sauty A, Rochat TH, Schoch O, et al. Pulmonary fibrosis with pre-dominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J. 1997;10:2907-2912.
108. Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002;129:541-548.
109. Kourakata H, Takada T, Suzuki E, et al. Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia. Respirology. 1999;4:223-228.
110. Enomoto K, Takada T, Suzuki E, et al. Bronchoalveolar lavage fluid cells in mixed connective tissue disease. Respirology. 2003;8:149-156.
111. Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/ dermatomyositis. Rheumatol Int. 2001;21:89-93.
112. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. Ann Rheum Dis. 2000;59:257-262.
113. Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27:1164-1170.
114. Iwata Y, Wada T, Furuichi K, et al. Serum levels of KL-6 reflect disease activity of interstitial pneumonia associated with ANCA-related vasculitis. Intern Med. 2001;40:1093-1097.
115. Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39:428-430.
116. Kobayashi I, Yamada M, Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology. 2003;43:371-374.
117. Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology. 2000;39:632-636.
118. Fujita J, Dobashi N, Tokuda M, et al. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis. J Rheumatol. 1999;26:2377-2382.
119. Fujita J, Dobashi N, Ohtsuki Y, et al. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung. 1999;177:311-319.
120. Ihn H, Asano Y, Kubo M, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology. 2002;41:1268-1272.
121. Wong RC, Klingberg S, Wilson R. CA 15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol. 2002;29:2021-2022.
122. Hill C, Romas E, Kirkham B. Use of sequential DTPA clearance and high resolution computerized tomography in monitoring interstitial lung disease in dermatomyositis. Br J Rheumatol. 1996;35:164-166.
123. Greene N, Solinger A, Baughman R. Patients with collagen vascular disease and dyspnea. The value of gallium scanning and bronchoalveolar lavage in predicting response to steroid therapy and clinical outcome. Chest. 1987;91:698-703.
124. Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527-1533.
125. Fata F, Rathore R, Schiff C, et al. Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis. South Med J. 1997;90:227-230.
126. Maeda K, Kimura R, Komuta K, et al. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26:24-29.
127. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80:329-332.
128. Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36:519-523.
129. Mok C, To C, Szeto M. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol. 2003;32:181-183.
130. Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol. 1987;14:1045-1047.
131. Thompson J. Lung involvement in polymyositis. Med J Aust. 1971;1:1332-1333.
132. Thompson P, Mackay I. Fibrosing alveolitis and polymyositis. Thorax. 1970;25:504-507.
133. Grathwohl K, Thompson J, Riordan K, et al. Digital clubbing associated with polymyositis and interstitial lung disease. Chest. 1995;108:1751-1752.
134. Schwarz M, Matthay R, Sahn S, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine. 1976;55:89-104.
135. Kobayashi N, Takizawa H, Sugiyama H, et al. A case of dermatomyositis which rapidly developed to respiratory failure in the presence of pneumomediastinum. Nihan Kyobu Shikkan Gakkai Zasshi. 1989;27:848-854.
136. Mouri M, Nambu Y, Matsui M, et al. A case of interstitial pneumonia of polymyositis-dermatomyositis with various pathological findings in open lung biopsy. Nihon Kyobu Shikkan Gakkai Zasshi. 1993;31:629-635.
137. Ikuta N. Kondoh Y, Taniguchi H, et al. Rapidly progressing BOOP in a patient with positive anti-Jo-1 antibody: response to corticosteroid pulse and immunosuppressant therapy. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34:1156-1162.
138. Enoki T, Nakagami T, Murakami A, et al. A case of dermatomyositis with severe retinopathy in a patient who died of acute interstitial pneumonia. Nippon Ganka Gakkai Zasshi. 1997;101:441-445.
139. Ohmichi M, Sasaki-Date H, Morikawa Y, et al. A case of nonspecific interstitial pneumonia with amyopathic dermatomyositis efficiently treated with a combination of cyclosporin A and prednisone. Nihon Kokyuki Gakkai Zasshi. 2002;40:478-483.
140. Imokawa S, Sato A, Iwata M, et al. A case of bronchiolitis obliterans organizing pneumonia with positive anti-Jo-1 antibody preceding polymyositis. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:914-919.
141. Hsue YT, Paulas HE, Coulson WF. Bronchiolitis obliterans organizing pneumonia in polymyositis. J Rheuamtol. 1993;20:877-879.
142. Nagai Y, Negishi M, Tomioka S, et al. A case of polymyositis presenting histological picture of bronchiolitis obliterans organizing pneumonia with transbronchial biopsy specimens. Ryumachi. 1995;35:915-919.
143. Itoh T, Mitsuoka S, Uji M, et al. Successful combination chemotherapy with low-dose methotrexate and steroids for dermatomyositis complicated by interstitial pneumonitis. Nihon Kokyuki Gakkai Zasshi. 1999;37:636-640.
144. Takashi H, Matsumoto T, Abe T, et al. A case of polymyositis with anti-Jo-1 antibody preceded by BOOP. Nihon Rinsho Meneki Gakkai Kaishi. 1998;21:87-94.
145. Knoell KA, Hook M, Grice DP, et al. Dermatomyositis associated with bronchiolitis obliterans organizing pneumonia. J Am Acad Derm. 1999;40:328-330.
146. Ozawa Y, Kurosaka D, Hashimoto N. An autopsy case of dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi. 1995;18:552-558.
147. Nobutoh T, Kohda M, Doi Y, et al. An autopsy case of dermatomyositis with rapidly progressive diffuse alveolar damage. J Dermatol. 1998;25:32-36.
148. Nagai Y, Ishikawa O, Miyachi Y. Pneumomediastinum and subcutaneous emphysema associated with fatal interstitial pneumonia in dermatomyositis. J Dermatol. 1997;24:482-484.
149. High W, Cohen J, Murphy B, et al. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J Am Acad Dermatol. 2003;49:295-298.
150. Al-Janadi M, Smith C, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989;16:1592-1596.
151. Sandbank M, Grunebaum M, Katzenellenbogen I. Dermatomyositis associated with subacute pulmonary fibrosis. Arch Dermatol. 1966;94:432-435.
152. Fernandes J, Goodwill C. Dermatomyositis without apparent myositis, complicated by fibrosing alveolitis. J Royal Soc Med. 1979;72:777-779.
153. Ferguson R, Davidson N, Nuki G, et al. Dermatomyositis and rapidly progressive fibrosing alveolitis. Thorax. 1983;38:71-72.
154. Weaver A, Brundage B, Nelson R, et al. Pulmonary involvement in polymyositis: report of a case with response to corticosteroid therapy. Arthritis Rheum. 1968;11:765-773.
155. Kalenian M, Zweiman B. Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies - an interesting association. Clin Diagn Lab Immunol. 1997;4:236-240.
156. Duncan P, Griffin J, Garcia A, et al. Fibrosing alveolitis in polymyositis: a review of histologically confirmed cases. Am J Med. 1974;57:621-626.
157. Iwata M, Sato A, Kitazawa H, et al. Clinicopathologic study of various lung diseases with bronchiolitis obliterans organizing pneumonia (BOOP) pattern in open lung biopsy. Nihon Kyobu Shikkan Gakkai Zasshi. 1991;29:1582-1590.
158. Imasaki T, Yoshii A, Tanaka S, et al. Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Intern Med. 1996;35:231-235.
159. Webb D, Currie G. Pulmonary fibrosis masking polymyositis. remission with corticosteroid therapy. JAMA. 1972;222:1146-1149.
160. Park S, Nyhan W. Fatal pulmonary involvement in dermatomyositis. Am J Dis Child. 1975;129:723-726.
161. Krain L. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol. 1975;111:241-245.
162. Olsen G, Swenson E. Polymyositis and interstitial lung disease. Am Rev Respir Dis. 1972;105:611-617.
163. Lin Y, Yang Y, Lin Y, et al. Steroid refractory interstitial pneumonitis in a patient with juvenile dermatomyositis. J Microbiol Immunol Infect. 2002;35:259-261.
164. Miyake S, Ohtani Y, Sawada M, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoid Vasc Diffuse Lung Dis. 2002;19:128-133.
165. Chatte G, Boyer J. Interstitial fibrosing pneumopathy and dermatomyositis. Pulmonary histology and prognosis. Rev Mal Respir. 1992;9:634-635.
166. Francois-Devos G, Leleu O, Aubry P, et al. Bronchiolitis obliterans organizing pneumonia associated with dermatomyositis and antiphospholipid syndrome. Rev Mal Respir. 2002;19:249-251.
167. Peria P, Tolstuchow N, Verret JL. Pneumopathie Interstitielle Fibrosante Révélatrice D'une Dermatomyosite. La Presse Med. 1991;20:1685.
168. Falga T, Valero R, Cucurull C, et al. Recurrent bronchiolitis obliterans organizing pneumonia as first manifestation of polymyositis. Ann Med Intern. 1995;12:498-500.
169. Katzenstein A, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301-1315.
170. Katzenstein AA, Myers JL. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria. Am J Surg Pathol. 2000;24:1.
171. Travis WD, King TE, Bateman E, et al. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
172. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410-1415.
173. Epler G. Bronchiolitis obliterans organizing pneumonia. Semin Respir Infect. 1995;10:65-77.
174. Oddis C. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:492-497.
175. McCune W, Vallance D, Lynch J. Immunosuppressive drag therapy. Curr Opin Rheumatol. 1994;6:262-272.
176. Hebert C, Byrnes T, Baethge B, et al. Exercise limitation in patients with polymyositis. Chest. 1990;98:352-357.
177. Schwarz M, Sutarik J, Nick J, et al. Pulmonary capillaritis and diffuse alveolar hemorrhage: a primary manifestation of polymyositis. Am J Respir Crit Care Med. 1995;151:2037-2040.
178. Pace W, Decker J, Martin C. Polymyositis: report of two cases with pulmonary function studies suggestive of progressive systemic sclerosis. Am J Med Sci. 1963:322-332.
179. Cervera R, Ramirez G, Fernández-Solà J, et al. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease. BMJ. 1991;302:880-881.
180. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 1997;111:36-43.
181. Mariette X. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjögren's syndrome and polymyositis. J Rheumatol. 1994;21:772-773.
182. Byrnes T, Baethge B, Wolf R. Noninvasive cardiovascular studies in patients with inflammatory myopathy. Angiology J Vasc Dis. 1991;42:843-848.
183. Bunch T, Tancredi R, Lie J. Pulmonary hypertension in polymyositis. Chest. 1981;79:105-107.
184. Denbow C, Lie J, Tancredi R, et al. Cardiac involvement in polymyositis. A clinicopathologic study of 20 autopsied patients. Arthritis Rheum. 1979;22:1088-1092.
185. Schwarz M. Pulmonary and cardiac manifestations of polymyositis- dermatomyositis. J Thorac Imaging. 1992;7:46-54.
186. Riemekasten G, Opitz C, Audring H, et al. Beware of the heart: the multiple picture of cardiac involvement in myositis. Rheumatology. 1999;38:1153-1157.
187. Grateau G, Roux M-E, Franck N, et al. Pulmonary hypertension in a case of dermatomyositis. J Rheumatol. 1993;20:1452-1453.
188. Caldwell I, Aitchison J. Pulmonary hypertension in dermatomyositis. Br Heart J. 1956;18:273-276.
189. Barvaux V, Van Mullem X, Pieters T, et al. Persistent pneumomediastinum and dermatomyositis: a case report and review of the literature. Clin Rheumatol. 2001;20:359-361.
190. Isfer RS, Nakao SK, Cernea SS. Dermatomyositis associated with pneumomediastinum and subcutaneous cellular tissue emphysema. Br J Rheumatol. 1994;33:1092.
191. Kono H, Inokuma S, Nakayama H, et al. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis. 2000;59:372-376.
192. De Toro Santos F, Verea-Hernando H, Montera C, et al. Chronic pneumomediastinum and subcutaneous emphysema: association with dermatomyositis. Respiration. 1995;62:53-56.
193. Miyata M, Fukaya E, Takagi T, et al. Two patients with polymyositis or dermatomyositis complicated with massive pleural effusion. Intern Med. 1998;37:1058-1063.
194. Juarez M, Misischia R, Alarcon G. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am. 2003;29:163-184.
195. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Resales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999;17:289-296.
196. Shah N, Balakrishnan C, Mangat G, et al. Pulmonary nocardial infection and pseudomonas infection of the tongue in a patient with dermatomyositis. J Assoc Physician India. 2001;49:850-851.
197. Kristan S, Kern I, Music E. Invasive pulmonary aspergillosis. Respiration. 2002;69:521-525.
198. Lynch J, Schaberg D, Kissner D, et al. Cryptococcus laurentii lung abscess. Am Rev Respir Dis. 1981;123:135-138.
199. Kadoya A, Okada J, Likuni Y, et al. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186-1188.
200. Bachelez H, Schremmer B, Cadranel J, et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med. 1997;157:1501-1503.
201. Viguier M, Fouere S, de la Salmoniere P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine. 2003;82:82-86.
202. Fujita J, Tokuda M, Bandoh S, et al. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Rheumatol Int. 2001;20:81-84.
203. Hill C, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96-100.
204. Tsang K, Lam W, Ip M. Response of dermatomyositis co-existing with non-small cell lung cancer to chemotherapy. Respir Med. 1998;92:788-790.
205. Alam M, Morehead S, Weinstein MH. Dermatomyositis as a presentation of pulmonary inflammatory pseudotumor (myofibroblastic tumor). Chest. 2000;117:1793-1795.
206. Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int. 2001;21:106-111.